Skip to main content
SpringerLink
Log in

Perspektiven der „targeted therapy“

Perspectives for targeted therapy

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Primäres Ziel der Behandlung des Lungenkarzinoms ist die Verlängerung des Langzeitüberlebens unter Beibehaltung der Lebensqualität. Im Mittelpunkt steht dabei die systemische Therapie. Mit der Chemotherapie als bisher einziger systemischer Therapieform scheint jedoch ein Effektivitätsplateau auf nicht befriedigendem Niveau erreicht zu sein.

Neue systemische Therapieansätze aus dem Bereich der Molekularbiologie werden unter dem Begriff der „targeted therapy“ zusammengefasst. Während einige neu entwickelte Substanzen im randomisierten Vergleich keinen Vorteil gegenüber der herkömmlichen Therapie nachweisen konnten, gibt es jetzt erste große Studien, die einen eindeutigen Vorteil einzelner Substanzen belegen konnten.

Abstract

The main focus of lung cancer therapy is the improvement of long-term survival. At the present time chemotherapy has been the only available systemic therapy, however, this mode of therapy has reached a plateau of effectiveness. New molecular biological therapies are being developed which are referred to as targeted therapies. Besides some negative results, the first randomized studies demonstrate an increased survival using these new agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Sandler A, Gray R, Brahmer J et al. (2005) Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Proc ASCO 23:2s (abstr LBA 4)

    Google Scholar 

  2. Bissett D, O’Byrne K, von Pawel J et al. (2002) Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitibine and cisplatin in non-small cell lung cancer. Proc ASCO 21:296a (abstr 1183)

    Google Scholar 

  3. DeVore RF, Fehrenbacher RS, Herbdst RS et al. (2000) A randomized phase II tgrial comparing thuMab VEGF (Tcombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. Proc Am Soc Clin Oncol 19:1896 (abstr)

    Google Scholar 

  4. Fukuoka M, Yano A, Giaccone G et al. (2003) Multi-institutional randomized phase II trial of gefitinib fpr prevgiosly treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246

    Google Scholar 

  5. Gatzemeier U, Gorth G, Hirsh V et al. (2002) Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study. Proc Am Soc Clin Oncol 21:1185 (abstr)

    Google Scholar 

  6. Gatzemeier U, Pluzanska A, Szczesna A et al. (2004) Results of a phase III trial erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:7010 (abstr)

    Google Scholar 

  7. Gatzemeier U, Rosell R, Ramlau R et al. (2003) Cetuximab (C225) in combination with cisplatin/vinrelbine vs. ciplatin/Vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:2582 (abstr)

    Google Scholar 

  8. Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non.small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22:777–784

    Google Scholar 

  9. Herbst RS, Giaccone G, Schiller JH et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22:785–794

    Google Scholar 

  10. Herbst RS, Johnson DH, Mininberg E et al. (2005) Phase I/II trial evaluating th anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with th her-1/epidermal growtu factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544–2555

    Google Scholar 

  11. Herbst RS, Prager D, Hermann R et al. (2004) TRIBUTE — A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:7011 (abstr)

    Google Scholar 

  12. Johnson DH, Fehrenbacher L, Novotny WF et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191

    Google Scholar 

  13. Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal gowth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Google Scholar 

  14. Lynch TJ, Bell DW, Sordell R et al. (2004) Acitivating mutatations in the epidermal growth factor receptor underlying reponsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Google Scholar 

  15. Lynch TJ, Raju R, Lind M et al. (2003) Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 22:2504 (abstr)

    Google Scholar 

  16. Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: Correlation with clinical reponse to gefitinib therapy. Science 304:1497–1500

    Google Scholar 

  17. Perez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinats of tumor response and survival with erlotinib in patients with no-small-cell lung cancer. J Clin Oncol 22:3238–3247

    Google Scholar 

  18. Rosell R, Daniel C, Ramlau R et al. (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth receptor (EGFR) expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23:7012

    Google Scholar 

  19. Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens fpr advanced non-small cell lung cancer. N Engl J Med 346:92–98

    Google Scholar 

  20. Shepherd FA, Pereira J, Ciuleanu TE et al. (2004) A randomized placebo controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line chemotherapy. A National Cancer Institute of Canada Clinical Trails Group (NCU CTG) trial. Proc Am Soc Clin Oncol 23:18

    Google Scholar 

  21. Smylie M, Mercier R, Aboulafia D et al. (2001) Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc ASCO 20:307a (abstr 1226)

    Google Scholar 

  22. Thatcher N, Chang A, Pemberten K et al. (2005) Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSG) in patients with advanced non small cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc. of the American Association of Cancer Research 46:DSSLB

    Google Scholar 

  23. Yuen A, Halsey J, Gisher G et al. (2001) Phase I/II trial o fISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 18:1234 (abstr)

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Vortragstätigkeiten für die Firmen Lilly, Astra Zeneca, Roche.

Author information

Authors and Affiliations

  1. Ruppiner Kliniken GmbH, Neuruppin

    K.-M. Deppermann

  2. Klinik für Pneumologie, Ruppiner Kliniken GmbH, Fehrbelliner Straße 38, 16816 , Neuruppin

    K.-M. Deppermann

Authors
  1. K.-M. Deppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K.-M. Deppermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deppermann, KM. Perspektiven der „targeted therapy“. Pneumologe 2, 268–275 (2005). https://doi.org/10.1007/s10405-005-0051-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-005-0051-2

Schlüsselwörter

Keywords

Search

Navigation